American College of Cardiology Annual Meeting
Are you familiar with the results of the eicosapentaenoic acid (EPA) analysis of the REDUCE-IT trial? Find out the effect of EPA on heart failure by taking our pop quiz.
In this video, Deepak Bhatt, MD, MPH, overviews the findings from the eicosapentaenoic acid (EPA) analysis of the REDUCE-IT trial and what impact the results may have on the future of cardiovascular therapies.
Peripheral Artery Disease
In this podcast, William R. Hiatt, MD, provides insight into a new subgroup analysis of the VOYAGER-PAD trial, which revealed whether adding clopidogrel to the rivaroxaban and aspirin regime of a patient with peripheral artery disease at the time of revascularization is beneficial.
The FDA approved bempedoic acid for the lowering of LDL-C in February 2020. In this Q&A, Pam R. Taub, MD, provides insight into the novel therapy.